Excellence in therapeutic innovation
Dompé is a leading Italian biopharmaceutical company focusing on the development of innovative treatment solutions for rare and often orphan diseases in areas with unmet treatment needs, such as diabetes, organ transplants, ophthalmology and oncology. Dompé pursues this objective by promoting and actively participating in a network made up of the best names in each activity of the pharmaceutical industry, from research to development, from production to marketing.
An international presence
Founded in 1940, Dompé has its headquarters in Milan, major industrial and biotechnological research facilities in L’Aquila, and an R&D unit in Naples.
As part of its international development strategy, in 2014 Dompé opened its offices in New York, to coordinate the R&D activities in North America, while in 2015 Dompé opened its Tirana offices, where the Company markets its Primary Care products.
Innovation that supports research
Dompé concentrates on areas with still unsatisfied therapeutic needs, such as diabetes, organ transplantations, ophthalmology and oncology. In 2014 the Company invested 19% of its sales revenues in Research&Development. During the year, 14 clinical trials were initiated worldwide and are being conducted with the support of an international network consisting of 70 excellence research institutes. In 2015 Dompé expects to invest € 42.5 million in Research & Development, i.e. 25% of its revenues; there will be 21 clinical studies in progress involving a total of 1,200 patients and 200 research centres worldwide.
In line with its mission, Dompé supports companies that demonstrate a high level of dynamism in healthcare innovation, and particularly in biotechnologies.
- From 2011 majority shareholder of Philogen, an Italian-Swiss biotech company specialized in biopharmaceutical products for the treatment of cancer, rheumatoid arthritis and some ophthalmic diseases.
- In 2012, it acquired Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available.
- In the same year, it became the leading shareholder in AAA (Advanced Accelerator Applications), a leader in the field of molecular medicine that specialises in R&D, the production of radiopharmaceuticals for molecular imaging, and personalised medicine.